文献速递临床试验与 GCP

抗焦虑颗粒治疗焦虑障碍的多中心随机双盲安慰剂对照平行组试验

The efficacy and safety of 'antianxiety granule' for anxiety disorder: a multicentre, randomized, double-blind, placebo-controlled, parallel-group trial.
PubMed 文献 · Trials · 2020-01-23

本研究为多中心、随机、双盲、安慰剂对照、平行组临床试验,计划纳入广泛性焦虑障碍(GAD)患者,给予抗焦虑颗粒或安慰剂治疗6周,以汉密尔顿焦虑量表(HAMA)、状态-特质焦虑问卷(STAI)及中医症状量表评分变化评估疗效与安全性。

要点

  • 抗焦虑颗粒治疗GAD的疗效与安全性尚待本试验结果验证。
  • 主要疗效指标为HAMA、STAI及中医症状量表评分变化。
  • 试验采用ITT分析,治疗期6周,随访1周。

核心结论

  • 本试验旨在评估抗焦虑颗粒治疗广泛性焦虑障碍的临床疗效与安全性,结果尚待报告。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照、平行组临床试验,治疗期6周。
  • 研究分筛选期1-7天、6周主要治疗期和1周随访期。
  • 采用意向性治疗(ITT)分析。

关键数值与推荐

  • 疗效评估采用汉密尔顿焦虑量表(HAMA)评分、状态-特质焦虑问卷(STAI)评分及中医症状量表评分变化。
  • 随访在末次访视后1周通过面对面或电话访谈进行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anxiety disorders are the most prevalent class of lifetime disorders in China, and generalized anxiety disorder (GAD) is one of the most common but frequently overlooked anxiety disorders. Conventional pharmacological treatments for GAD have varying degrees of side effects, dependency, and/or withdrawal syndromes. Traditional Chinese medicine (TCM) is considered a valuable therapeutic option for anxiety disorders and a potentially effective technique to reduce the side effects associated with antipsychotic drugs. This trial aimed to evaluate the clinical efficacy and safety of Antianxiety Granule, a granular Chinese medicine compound, for treatment of GAD. METHODS/DESIGN: The current work is a multicentre, randomized, double-blind, placebo-controlled, parallel-group clinical trial with a 6-week treatment schedule. The study consists of three periods: a 1-7-day screening period, a 6-week primary treatment period, and a 1-week follow-up period. Follow-up assessments will be conducted 1 week after the last visit with a face-to-face interview or by telephone. The clinical efficacy of Antianxiety Granule for the treatment of GAD will be evaluated by examining the change in the Hamilton anxiety scale (HAMA) score, state-trait anxiety inventory (STAI) score, and TCM symptom scale in patients with GAD who receive daily TCM treatment. Moreover, an intention-to-treat (ITT) analysis will also be used in this randomized controlled trial (RCT). DISCUSSION: Our study is a multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the safety and efficacy of Antianxiety Granule for the treatment of GAD. The results of this trial will provide valuable clinical evidence for the treatment of GAD. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR1800016039. Registered on 8 May 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sha Z, Hou Y, Xue C, et al. The efficacy and safety of 'antianxiety granule' for anxiety disorder: a multicentre, randomized, double-blind, placebo-controlled, parallel-group trial. Trials. 2020. PMID: 31973702. doi:10.1186/s13063-020-4057-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。